secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0000944809-22-000046
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health reports Q3 net loss of $86.1M as COVID testing revenue collapses
----------------------------------------------------------------------------

- Consolidated revenue $179.7M, down 53% YoY from $385.8M, driven by lower COVID-19 testing.
- Diagnostics revenue $142.8M (vs. $340.1M); BRL processed ~0.2M COVID PCR tests vs 2.2M last year.
- Pharmaceuticals revenue $32.4M (vs. $36.9M); NGENLA royalties began; RAYALDEE sales $6.9M.
- Operating loss $87.8M vs operating income $37.8M; net loss $0.11 per share vs $0.04 income.
- BRL cut >$100M annualized costs; cash and equivalents $180.8M at Sept. 30, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000094480922000046/0000944809-22-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000094480922000046/opk-20221108.htm
  HTML page:      https://secwatch.observer/filing/0000944809-22-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer